indomethacin
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
3320
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
September 29, 2026
Pericerclage tocolytics, antibiotics, or their combination and risk of preterm birth: a systematic review and meta-analysis.
(PubMed, Am J Obstet Gynecol MFM)
- "Adjunctive pericerclage therapy with tocolysis and/or antibiotics was not associated with reduced PTB or improved maternal and neonatal outcomes. Indication-specific analyses did not demonstrate a significant benefit in either UIC or PEIC. Point estimates for several outcomes favored adjunctive therapy in the PEIC subgroup; however, these findings are exploratory and should be interpreted cautiously. Further adequately powered, indication-specific studies are needed."
Journal • Retrospective data • Review
July 15, 2026
HN01001, A NOVEL POTASSIUM-COMPETITIVE ACID BLOCKER, DEMONSTRATES SUPERIOR AND SUSTAINED GASTRIC ACID SUPPRESSION FOR THE TREATMENT OF GASTRIC ACID-RELATED DISORDERS
(UEGW 2026)
- "In addition, HN01001 reduced total gastric acid output with a half maximal effective dose value of 0.323 mg/kg and provided greater and more sustained acid suppression than Vonoprazan in the Heidenhain pouch dog model. These findings indicate that HN01001 delivers enhanced potency and prolonged acid suppression relative to established P-CABs, supporting its potential as a best-in-class therapeutic agent for gastric acid-related disorders."
Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Peptic Ulcer
September 27, 2026
Vasorelaxant Effects of Wild Jujube Leaf Aqueous Extract: Endothelial NO/cGMP/SERCA Signaling, Antioxidant Activity, and AI-Based Molecular Docking.
(PubMed, Molecules)
- "Complete inhibition by endothelium denudation, and preincubation with L-NAME, hydroxocobalamin, ODQ, and thapsigargin confirmed endothelium-dependent nitric oxide (NO)/cyclic GMP (cGMP)/sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pathway involvement. A partial inhibition by BaCl2, indomethacin, calmidazolium, and KCl indicated cyclooxygenase (COX), endothelium-derived hyperpolarizing factor (EDHF), and inward-rectifier potassium (Kir) channel contributions...The presence of flavonoids in the ZLAqExt might have mediated its vasorelaxant effects, supporting its traditional use as an antihypertensive. Our results highlight that Z. lotus is a potential natural therapeutic agent against vascular dysfunction-related cardiovascular disorders."
Journal • Cardiovascular • Hypertension
September 27, 2026
Fixed-dose combination of poorly water-soluble drugs, indomethacin and carbamazepine, formulated as a multi-composed amorphous solid dispersion: a potential therapy for HC-tic (part 1).
(PubMed, Int J Pharm)
- "Furthermore, the MC-ASDs exhibited good physical stability. Overall, multi-composed ASDs represent a promising approach for the development of fixed-dose combinations of poorly water-soluble drugs."
Journal • Gastrointestinal Disorder • Musculoskeletal Pain • Neuralgia • Pain
September 27, 2026
Green-Synthesized Mesoporous Silica-Enhanced Herbal Nanofibers with Antimicrobial, Anti-Inflammatory, and Biocompatible Wound Healing Potential.
(PubMed, Molecules)
- "In lipopolysaccharide-stimulated RAW 264.7 macrophages, the optimized formulation reduced nitric oxide production by approximately 51%, comparable to indomethacin and L-NAME. Although fibroblast migration was not significantly enhanced, the nanofibers exhibited acceptable cytocompatibility and showed no mutagenic or genotoxic effects in Ames and comet assays. These findings demonstrate that green-synthesized MSN-enhanced herbal nanofibers represent a safe and promising platform for sustained drug delivery and advanced wound-healing applications."
Journal • Infectious Disease • Inflammation
September 27, 2026
Effect of Rosifoliol/Agarospirol and 7α-Hydroxysandaracopimaric Acid from Salvia elegans Vahl on Local Inflammation and LPS-Activated RAW-Blue Cells.
(PubMed, Molecules)
- "SeAcOEt inhibited TPA-induced ear edema by 87.3%, whereas SeFB showed the highest activity (97.4%), comparable to indomethacin...The anti-inflammatory activity of S. elegans could be associated with the combined contribution of phytochemicals enriched in the bioactive fraction SeFB rather than with a single active constituent. This study expands the phytochemical knowledge of S. elegans by reporting 7α-hydroxysandaracopimaric acid and provides pharmacological evidence supporting the traditional use of this species for inflammatory conditions."
Journal • Inflammation
September 26, 2026
Soybean fermentation broth alleviates indomethacin-induced gastric mucosal injury.
(PubMed, J Food Drug Anal)
- "Furthermore, SFB suppressed pro-inflammatory mediator expression and favorably modulated cyclooxygenase-1 (COX-1) and COX-2 expression, accompanied by restoration of prostaglandin E2 (PGE2) production. These findings indicate that SFB protects gastric mucosa against indomethacin-induced injury through coordinated regulation of oxidative stress, inflammatory signaling, and prostaglandin-mediated mucosal defense, supporting its potential as a functional fermented soybean product."
Journal • Peptic Ulcer • CAT • PTGS2
September 25, 2026
Variations in diagnosis and management of hemodynamically significant patent ductus arteriosus across neonatal intensive care units in the Children's Hospitals Neonatal Consortium.
(PubMed, J Perinatol)
- "A majority of CHNC centers maintain written hsPDA guidelines incorporating clinical and echocardiographic criteria. Management emphasizes a stepwise approach from expectant to active management with pharmacotherapy and increasing adoption of transcatheter closure, highlighting evolving practice patterns in neonatal PDA care."
Journal • Critical care
August 29, 2026
Predictors of Unplanned Healthcare Encounters After Endoscopic Retrograde Cholangiopancreatography: Experience From a Prospectively Followed Cohort
(ACG 2026)
- "Antibiotic use was associated with lower odds of UHE (aOR 0.12, 95% CI 0.02â0.63), whereas indomethacin use was not (aOR 0.43, 95% CI 0.05â3.58)... Of 431 patients (53% male; mean age 58 ± 15.2 years), 53 (12.3%) patients had at least one UHE within 30 days after ERCP (Table 1). A history of pancreatic cancer (aOR 12.1, 95% CI 1.01â146.2), cholangiocarcinoma (aOR 28.2, 95% CI 1.2â682.6), hepatocellular carcinoma (aOR 6.5, 95% CI 1.1â39.0), and metastatic cancer (aOR 6.5, 95% CI 1.7â153.3) were associated with increased odds of UHE, whereas liver transplant was not significantly associated with UHE (aOR 3.0, 95% CI 0.5â19.4). Among ERCP indications, pancreatic duct stricture (aOR 13.8, 95% CI 1.2â155.7) and pancreatic mass (aOR 3.2, 95% CI 1.4â7.5) were associated with higher odds of UHE (Figure 1)."
Clinical • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Pancreatic Cancer • Solid Tumor
August 29, 2026
Zero Post-ERCP Pancreatitis With Systematic Indomethacin Prophylaxis in Pregnancy: Largest Mexican Cohort
(ACG 2026)
- "Mean age 25.8 ± 5.5 years; gestational age at ERCP 19.0 ± 7.2 weeks. Indications: choledocholithiasis (44.4%), cholangitis (22.2%), biliary pancreatitis (22.2%). Indomethacin administered in 25/27 (92.6%); 2 contraindicated (renal dysfunction, NSAID allergy)."
Hematological Disorders • Hepatology • Immunology • Nephrology • Obstetrics • Pancreatitis • Renal Disease
August 29, 2026
Rectal Diclofenac Versus Indomethacin for Prevention of Post-ERCP Pancreatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
(ACG 2026)
- "Two RCTs comprising 1,450 patients met inclusion criteria (724 diclofenac, 726 indomethacin). PEP occurred in 8.0% of patients receiving diclofenac and 6.1% receiving indomethacin. Diclofenac was not associated with reduced PEP risk compared with indomethacin (RR 1.32, 95% CI 0.91â1.93; I²=28.5%)."
Retrospective data • Review • Pancreatitis
September 25, 2026
When a side-locked headache becomes a stroke code: indomethacin-responsive hemicrania continua with transient hemiplegia.
(PubMed, Proc (Bayl Univ Med Cent))
- "Emergent multimodal neuroimaging was negative; intravenous tenecteplase was administered for suspected ischemic stroke. After the postthrombolysis safety window, an oral indomethacin trial led to complete headache resolution and rapid clearing of deficits. This case illustrates that hemicrania continua can manifest with hemiplegic features due to overlapping cortical spreading depression biology and highlights the diagnostic utility of an inpatient indomethacin trial."
Journal • Cardiovascular • CNS Disorders • Depression • Ischemic stroke • Migraine • Ophthalmology • Pain • Psychiatry
September 24, 2026
Photoinitiator-free gelatin hydrogel microneedles for acute gouty arthritis treatment.
(PubMed, Sci Adv)
- "The NPs are composed of natural polyphenols and indomethacin...Further in vivo evaluation in an acute gouty arthritis model demonstrated that the MN system could significantly alleviate joint inflammation through rapid drug release, highlighting its potent anti-inflammatory efficacy. Overall, this initiator-free, photo-crosslinkable GelLA-based MNs system offered a safe, efficient, and user-friendly strategy for local drug delivery in the management of acute gouty arthritis."
Journal • Immunology • Inflammation • Inflammatory Arthritis • Rheumatology
September 24, 2026
Drug repurposing identifies candidate uterus-selective tocolytics for preterm labor.
(PubMed, Sci Transl Med)
- "Of these, two drugs, the antiemetic fosaprepitant dimeglumine and the glucocorticoid ciclesonide, displayed favorable in vitro therapeutic indices (TIs > 5), inhibited contractions in human myometrial tissue ex vivo, and did not alter tone in the fetal murine ductus arteriosus ex vivo...Four synergistic drug combinations incorporating ciclesonide, indomethacin, ivermectin, atosiban, or nelfinavir mesylate displayed favorable TIs of >5 and improved ex vivo tocolytic potency, efficacy, or both. Last, aprepitant, ciclesonide, and four synergistic drug combinations delayed delivery until term and improved neonatal viability and skin and lung maturation in a mouse model of induced preterm labor, with several combinations outperforming their component drugs. This approach established a systematic strategy for identifying uterus-selective tocolytics, and these findings support further preclinical development of repurposed drugs and drug combinations for the..."
Journal
September 23, 2026
Indomethacin as a Multi-target Anticancer Agent via Transmembrane Receptor-mediated Tumor Suppression: The Need for de novo Drug Derivatization.
(PubMed, Curr Drug Targets)
- "Despite the possibility of using indomethacin as a template structure for creating more selective drugs, it seems that indomethacin cannot serve as a drug for anticancer therapy alone. This conclusion specifically positions parent indomethacin as a chemically modifiable scaffold for rational derivative development rather than as a final therapeutic endpoint."
Journal • Breast Cancer • Colorectal Cancer • Genito-urinary Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • CXCR3 • FGFR
September 23, 2026
Design, synthesis, structure-activity relationship and in-silico studies of novel pyrazolo[1,5-a]pyrimidine derivatives as selective COX-2 inhibitors with promising anti-inflammatory activity and safety profile.
(PubMed, Bioorg Chem)
- "Nine representative compounds spanning both high- and low-selectivity chemotypes were evaluated in a formalin-induced paw edema model, chosen over carrageenan for its chronic, biphasic inflammatory profile: 8a displayed 1.5-fold higher potency than indomethacin and 1.45-fold over celecoxib (p < 0.0001), while 8i achieved 1.25-1.30-fold and 1.6-fold relative potency (p < 0.01). Molecular docking, 100 ns MD simulations, and MM-GBSA binding free energy calculations further confirmed stable active-site binding (ΔGbind = -54.32 and - 56.14 kcal/mol for 8a and 8i, respectively). Collectively, these integrated results establish 8a and 8i as potent, selective, and structurally stable lead candidates for preclinical COX-2 inhibitor development."
Journal • IL6
September 22, 2026
Design, Synthesis and Pharmacological Profiling of Amino Acid-based Indomethacin Conjugates: A Strategy to Mitigate Gastrointestinal Toxicity.
(PubMed, Antiinflamm Antiallergy Agents Med Chem)
- "The findings of this study suggest that amino acid conjugation can overcome the limitations of conventional NSAIDs and represents an effective strategy for developing safer, more selective COX-2 inhibitors."
Journal • Hematological Disorders
September 16, 2026
Computational, In Vitro, and In Vivo Evaluation of Benzimidazole-Pyrazole Hybrid Scaffolds as Multi-Target Anti-Ulcer Agents.
(PubMed, Chem Biodivers)
- "Molecular docking into H+/K+-ATPase (PDB ID: 5YLU) and COX-2 (PDB ID: 3LN1) enzymes predicted high affinity of these compounds with docking scores of -9.4 and -9.3 kcal/mol for compounds 5i and 5e, respectively, higher than those obtained for the reference drugs omeprazole and celecoxib...Studies on the ethanol and indomethacin-induced gastric ulceration models demonstrated good inhibitory effects of these compounds...Acute oral toxicity studies indicated no observable toxicity at 100 mg/kg. Collectively, these findings identify compounds 5i and 5e as promising multifunctional gastroprotective candidates warranting further pharmacological investigation."
Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Peptic Ulcer • MPO • TNFA
September 20, 2026
BASAL RELEASE OF 6-CYANODOPAMINE AND 6-NITRODOPAMINE FROM RAT ISOLATED AORTA AND THEIR ROLE IN VASCULAR RELAXATION.
(PubMed, Eur J Pharmacol)
- "Vascular reactivity was assessed in U-46619-precontracted rings with intact or removed endothelium and after pharmacological inhibition with Nω-nitro-L-arginine methyl ester (L-NAME), 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), indomethacin, SQ-22536, SCH-23390, and haloperidol...SQ-22536 also attenuated forskolin- and iloprost-induced relaxation, supporting involvement of adenylyl cyclase/cAMP signaling in 6-CYD responses...Rat thoracic aorta basally releases 6-CYD and 6-ND, and although both act as potent vasodilators, they have distinct mechanisms of action. These findings shed new light on mechanisms by which the vascular endothelium regulates vascular tone."
Journal • Preclinical • Cardiovascular • Hypertension
September 18, 2026
Green synthesis of pyridine-benzofuran hybrids with anti-inflammatory activity alongside in silico study.
(PubMed, iScience)
- "Among all tested compounds, 7a and 7e demonstrated the most potent dose-dependent inhibition, reaching 61.2% and 60.3% at 200 mg/kg (∗∗p < 0.001), respectively, compared with indomethacin (78.5% at 10 mg/kg)...Integrating in vivo and in silico findings, compounds 7a and 7f emerged as top candidates. Compound 7a was selected for a 100-ns molecular dynamics simulation, which confirmed the stability of the ligand-protein complex and sustained effective interactions with the enzyme, establishing 7a as a promising anti-inflammatory lead candidate."
Journal • Inflammation
September 18, 2026
Profiles of nonsteroidal anti-inflammatory drug-induced gastric antral ulcers: A comprehensive review of the preclinical data.
(PubMed, J Pharmacol Exp Ther)
- "Dietary supplementation with taurocholate aggravated indomethacin-induced AUs, whereas cholestyramine, a bile acid sequestrant, attenuated them. SIGNIFICANCE STATEMENT: Nonsteroidal anti-inflammatory drug-induced gastric ulcers are induced dependently on feeding conditions, dietary fibers, intragastric bile acids, gastric motility, and stress. This review summarizes the recent advances and provides new insights into the pathogenesis of nonsteroidal anti-inflammatory drug-induced foregut mucosal injury and may contribute to novel and effective pharmacological approaches for ulcer prevention in humans."
Journal • Preclinical • Review • Gastrointestinal Disorder • Peptic Ulcer • HRH2
September 18, 2026
Extraction of indomethacin from plasma based on V2O5.1·6H2O sorbent using dispersive solid phase extraction method prior to HPLC-MS/MS determination.
(PubMed, J Chromatogr A)
- "Validation results indicated a wide linear range (5-150 ng mL-1), acceptable coefficient of determination (0.995), and low limits of detection (0.2 ng mL-1), and quantification (0.7 ng mL-1), as well as good precision (relative standard deviations ≤ 6.0% for intra-day (n = 7) and inter- (n = 5) precisions). These findings demonstrated the high potential of the proposed method for screening indomethacin in human plasma samples."
Journal
July 31, 2026
Pharmacological Interventions for the Prevention of Esophagitis in Lung Radiation: Systematic Review and Meta-Analysis
(IASLC-WCLC 2026)
- "Eight trials reported survival or treatment response outcomes, all of which showed no difference between trial arms Conclusions : Previous clinical trials have investigated the role of amofostine, epoetin-alpha, indomethacin, naproxen, glutamine and sodium alginate in preventing radiation-induced esophagitis in lung cancer. Pooled analysis demonstrates promising results for amfostine."
Retrospective data • Review • Gastrointestinal Disorder • Lung Cancer • Solid Tumor
September 15, 2026
Dichloroacetonitrile formation from anthropogenic aromatic compounds during chlorination: Identification of structural characteristics and development of a predictive flowchart.
(PubMed, J Hazard Mater)
- "Based on these findings, a practical flowchart was developed to qualitatively predict the DCAN yield categories (high/medium/low) and was applied to four structurally complex compounds (N-(1,3-dimethylbutyl)-N'-phenyl-1,4-phenylene diamine (6PPD), amodiaquine, indomethacin, and prilocaine). This illustrates the utility of the flowchart as a proactive screening tool for anthropogenic compounds with high DCAN formation potential, thereby supporting water quality management and risk assessment."
Journal
September 13, 2026
Pullulan acetate with tailored degree of substitution as a promising polymer for oral drug delivery: Effects on enzymatic degradability and drug release.
(PubMed, Int J Pharm)
- "Enzymatic degradability was evaluated using pullulanase type I as a simplified model to probe polymer accessibility, and drug-release behaviour was studied using indomethacin-loaded PA/HPMC matrix tablets, with comparison to conventional EC/HPMC systems...These findings demonstrate that controlled variation of DS enables systematic tuning of both enzymatic behaviour and drug-release performance in polysaccharides. In addition, PAs provide a useful model system for studying DS-dependent structure-property relationships and demonstrate potential for use in sustained oral drug delivery applications."
Journal
1 to 25
Of
3320
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133